Breast Conservative Therapy Viable in Male Breast Cancer
Mastectomy is significantly more common than breast conservative therapy (BCT) among male breast cancer (MBC) patients, but a retrospective analysis of 11,406 men with stage I to III breast cancer found better survival with BCT. The men were included in the National Cancer Database between 2004 and 2015, and none had Paget’s, T4/inflammatory breast cancer, or multicentric disease.
In the study, 6,326 (55%) men underwent mastectomy alone, 2,162 (19%) underwent mastectomy with radiation, 2,085 (18%) underwent BCT, and 833 (7%) underwent lumpectomy alone. Compared with both mastectomy cohorts, BCT was associated with younger age, smaller tumors, and lower nodal disease rates. In the multivariate model, BCT was associated with improved survival compared with mastectomy alone (hazard ratio [HR], 1.69; 95% confidence interval [CI], 1.44-1.98; P<.001), mastectomy with radiation (HR, 1.52; 95% CI, 1.27-1.83; P<.001), and lumpectomy alone (HR, 1.91; 95% CI, 1.56-2.33; P<.001). Factors associated with poorer survival included older age; increased T stage, N stage, and/or histological grade; and triple-negative hormone receptor/HER2 positivity (P<.05).
Read more here.
Reference
Bateni S, Davidson AJ, Arora M, et al. Comparison of breast conservative therapy to mastectomy in male breast cancer: a NCDB analysis. Presented at: 2018 American Society of Clinical Oncology; June 1-5, 2018; Chicago, Illinois. Abstract 565.
